Recombinant Rat Fractalkine (FKN)

Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium¹ that mediates attachment and firm adhesion of T cells, monocytes and NK cells.² FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.³ FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).⁴

The biological activity of Rat CX3CL1 was determined by its ability to chemoattract freshly isolated human peripheral blood lymphocytes (PBL). The expected ED₅₀ is 0.03 - 0.06 μg/ml.

qhlgmt kcnitchkmt spipvtllih yqlnqescgk raiiletrqh rhfcadpkek wvqdamkhld hqtaaltrng gkfekrvdnv tpritsatrg lsptalakpe satvedltle ptaisqearr pmgtsqeppa avtgsspsts kaqdaglaak pqstgiseva avsttiwpss avyqsgsslw aeekatespp tialstqast tsspkqnvgs egqppwvqeq dstpekspgp eetnpvhtdi fqdrgpgstv hpsvaptsse ktpspelvas gsqapkveep ihatadpqkl svfitpvpds qaat

Lyophilized

The predicted molecular weight of Recombinant Rat CX3CL1 is Mr 22 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 100 kDa.

22

This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Block, ML. et al. (2011) Environ Health Perspect.119(8):1149-55. doi: 10.1289/ehp.1002986. PubMed
2. Patel, DD et al. (1998) J Exp Med. 188: 1413
3. Hwang, ST et al. (1999) Eur J Immunol. 29: 2551
4. Muller, GA et al. (2008) Z Rheumatol. 67: 424
5. Mori, M et al. (2005) Int J Oncol. 26: 41